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Detailed molecular characterisation of acute myeloid leukaemia
with a normal karyotype using targeted DNA capture
N Conte1,2,8, I Varela3,8, C Grove1, N Manes1, K Yusa1, T Moreno3, A Segonds-Pichon4, A Bench5, E Gudgin5, B Herman6, N Bolli1,5,
P Ellis1, D Haddad1, P Costeas7, R Rad1, M Scott5, B Huntly5, A Bradley1 and GS Vassiliou1
Advances in sequencing technologies are giving unprecedented insights into the spectrum of somatic mutations underlying acute
myeloid leukaemia with a normal karyotype (AML–NK). It is clear that the prognosis of individual patients is strongly influenced by
the combination of mutations in their leukaemia and that many leukaemias are composed of multiple subclones, with differential
susceptibilities to treatment. Here, we describe a method, employing targeted capture coupled with next-generation sequencing
and tailored bioinformatic analysis, for the simultaneous study of 24 genes recurrently mutated in AML–NK. Mutational analysis was
performed using open source software and an in-house script (Mutation Identification and Analysis Software), which identified
dominant clone mutations with 100% specificity. In each of seven cases of AML–NK studied, we identified and verified mutations in
2–4 genes in the main leukaemic clone. Additionally, high sequencing depth enabled us to identify putative subclonal mutations
and detect leukaemia-specific mutations in DNA from remission marrow. Finally, we used normalised read depths to detect copy
number changes and identified and subsequently verified a tandem duplication of exons 2–9 of MLL and at least one deletion
involving PTEN. This methodology reliably detects sequence and copy number mutations, and can thus greatly facilitate the
classification, clinical research, diagnosis and management of AML–NK.
Leukemia (2013) 27, 1820–1825; doi:10.1038/leu.2013.117
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INTRODUCTION
Advances in DNA sequencing technologies are revolutionising our
understanding of the genetic basis of cancer.1 One of the first
cancers studied by whole-genome sequencing was acute myeloid
leukaemia with a normal karyotype (AML–NK),2,3 a disease whose
molecular aetiology was, until recently, poorly understood.
As a result, we now know of more than 10 genes mutated in
45% of cases of AML–NK and of several others mutated less
often.4–6 Additionally, it has become clear that mutations other
than those affecting FLT3,7 NPM18 and CEBPA9 have a significant
impact on prognosis and can help stratify anti-AML therapy for
individual patients.4 In this light, many are calling for a shift
towards a classification system for AML–NK based primarily on
mutational profiling.4
Currently, many diagnostic laboratories routinely screen for
mutations in NPM1 and FLT3, both of which show clustering of
somatic mutations in 1–3 exons. However, mutational screening
for genes such as CEBPA and TET2, which do not exhibit mutation
clustering, is only employed in specialist laboratories. Further-
more, with the identification of an increasing number of mutant
genes in AML, detailed molecular genotyping can no longer be
practicably performed using conventional molecular methods
such as capillary sequencing or melt curve analyses. Moreover,
modern sequencing technologies have demonstrated that many
cases of AML are composed of several related subclones, arising
through the acquisition of different somatic mutations during
clonal evolution from a single-ancestral cell.6,10 These clones are
often invisible to conventional diagnostic methods, yet they
commonly represent a significant, if not the main, clone at the
time of leukaemia relapse.10 As relapse is the main vehicle for the
poor prognosis of AML, the detection of clones carrying adverse
mutations at the time of diagnosis can help identify and stratify
high-risk patients.
Given the above, a full molecular diagnostic evaluation of AML
requires the identification of all mutations with prognostic or
therapeutic significance in the main clone, as well as in subclones
when these are present. Here we successfully employ targeted
DNA capture with cRNA baits followed by deep sequencing and
tailored informatics to simultaneously study 24 genes known to be
recurrently mutated in AML–NK and 10 control genes.
MATERIALS AND METHODS
Leukaemic DNA samples
DNA samples from total bone marrow cells, excess to diagnosis, were
obtained after informed consent within our ethics-approved study
(07/MRE05/44) from seven patients with AML–NK. Remission samples
were obtained from two of these patients and a relapse sample from one.
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Bait design
We designed a set of Sure Select cRNA biotinylated oligonucleotide baits
(Agilent Technologies, Palo Alto, CA, USA) to capture all exons from a set of
24 genes known to be recurrently mutated in AML and 10 control genes,
some known to be mutated in solid tumours (Table 1). The custom bait
library was designed using eArray software (Agilent Technologies). The
exons of the 34 genes were downloaded from Biomart (http://www.en-
sembl.org/biomart/martview/) and used to create 120 bp baits starting
every 24 bp. The masking option used was ‘RepeatMasker’ and the
software allowed baits to overlap by a maximum of 20 bp with repeat
masked regions. The centred design strategy was used, which ensured that
the tiling level was maintained and baits were not ‘squeezed’ in the
specified interval. As a result, the input region could be expanded by 20 bp
at each end. The concentration of individual baits was adjusted manually
depending on the target nucleotide composition to optimise DNA capture
GC-rich regions (n¼ 1579) had 2x and orphan regions (n¼ 649), defined
as those covered by a single bait, 5x more bait molecules per locus than
standard regions (n¼ 5997). The total target region size was 24 2051
nucleotides and the library design is available under the unique ELID
reference: 0324251.
DNA target selection by ‘pull-down’
DNA fragmentation, library preparation and solution phase hybrid capture
were performed according to manufacturer’s instructions (Agilent
Technologies) and modified from previously published protocols.11
Sequencing and mapping
We sequenced 10 samples on a single multiplexed lane on an Illumina
HiSeq 2000 and aligned the resulting reads to the hg19 reference genome
with BWA (Burrows–Wheeler Alignment; http://bio-bwa.sourceforge.net/
bwa.shtml).12
Coverage and statistical analysis
Coverage histograms and tables describing the coverage distribution for
our set of targeted bases were produced using TEQC, ‘Target Enrichment
Quality Control’ Bioconductor package.13 To validate the ability of
our assay to identify copy number changes, we used read numbers of
two X-linked genes (HPRT and KDM6A). First, we generated a list of non-
redundant ‘amalgamated exons’, each representing all overlapping
annotated exons. Read count normalisation was done using open-source
software and bespoke R scripts: for each sample, read counts per position
were calculated using Bedtools 2.12.0 (http://code.google.com/p/
bedtools),14 then normalised read counts were calculated by averaging
the exon-specific read counts and dividing by the total number of mapped
reads for that sample. As DNA quality can affect capture efficiency and thus
read counts, we first wanted to ensure all 10 samples gave comparable
standardised read depths for the majority of target regions. For this, we
looked at the average read count for each patient at each gene. Sample P5
was an outlier for 23 of the 34 genes and was removed from copy number
calculations. All other samples were outliers for three genes or less
(Supplementary Figure S1). To identify copy number variation at individual
exons, we calculated the coefficient of variability for each exon for the nine
patients. We then used the Tukey boxplot approach to identify the outlier
exons (4upper quartileþ 1.5*IQR, interquartile range). Data from genes
with an increased coefficient of variability at more than one exon were
examined manually. The mixed-lineage leukaemia (MLL) deletion was also
detected by analysis with ExomeCopy (http://www.bioconductor.org/
packages/2.11/bioc/html/exomeCopy.html).
Mutation calling
Alignment and post-processing. Fastq files were aligned against the
human genome (hg19 version) using BWA algorithm (v 0.5.9). Afterwards
SAMTOOLS (0.1.18) view, sort, index and fixmate algorithms were used to
generate, sort, index and fix co-ordinates of the generated bam files.
PICARD (v1.61) java libraries were used to mark PCR duplicates and finally
GATK (v. 1.4.20) tools were used to perform local realignment around
indels. All these steps were automated using a single in-house written
script available upon request.
Variant calling. SAMTOOLS pileup command was used to generate pileup
files from the generated bam files (version 0.1.8) (http://samtools.source-
forge.net/).15 A flexible in-house Perl script (MIDAS, Mutation Identification
and Analysis Software; available upon request) was created to parse the
pileup file and to take into account in each position only those reads with a
sequence quality higher than 25 and a mapping quality higher than 15,
and consider only those positions that had a coverage of at least 10 both in
the tumour and in the control sample (unless otherwise stated, P1CR was
used as control for all comparisons). On those positions, and taking into
account the high coverage obtained in this experiment, we reported the
possible existence of a substitution whenever there was at least 20
independent reads reporting a different base vs the reference genome in
the tumour sample and less than 5% of the reads reporting the same
variant in the control sample. We also discarded those positions with at
least one-third of this evidence reporting a third allele, as we consider that
those regions would probably represent difficult sequences for the aligner
and would likely produce false positives. We considered variants present in
420% of reads as those representing the main/dominant leukaemic clone.
In the case of indels (small insertions and deletions), we considered
positive those regions with at least 10 independent reads reporting the
same indel in the tumour sample and with less than 5 reads in the control
sample, and with at least 10 times more reads reporting the indel in the
tumour vs the control sample. Similarly to what we did with substitutions,
those regions with an evidence of a second indel higher than 40% of the
evidence for the primary indel were discarded. Our workflow is shown in
Figure 1. Of note, MIDAS allows adjustment of tolerance thresholds to suit
the type of control sample used (for example, they can be increased to
facilitate the use of a remission sample as a control, which may harbour
residual low-level mutant reads).
Comparison with other software/algorithms. The performance of our
software was checked using independent variant calling algorithms. In
particular, we run SomaticSniper (v. 1.0.2; http://gmt.genome.wustl.edu/
Table 1. Genes analysed by targeted capture
Gene ID Chromosome Position (Mb)
AML genes
NRAS 1 115.2
DNMT3A 2 25.5
SF3B1 2 198.3
IDH1 2 209.1
KIT 4 55.5
TET2 4 106.1
CSF1R 5 149.4
NPM1 5 170.8
EZH2 7 148.5
JAK2 9 5.0
PTEN 10 89.6
WT1 11 32.4
MLL 11 118.3
CBL 11 119.1
KRAS 12 25.4
PTPN11 12 112.9
FLT3 13 28.6
IDH2 15 90.6
TP53 17 7.6
NF1 17 29.4
CEBPA 19 33.8
ASXL1 20 30.9
RUNX1 21 36.2
KDM6A X 44.7
Control genes
UGT1A1 2 234.7
PIK3CA 3 178.9
IKZF1 7 50.3
EGFR 7 55.1
BRAF 7 140.4
XRCC2 7 152.3
PAX5 9 36.8
TLR4 9 120.5
CYP2D6 22 42.5
HPRT1 X 133.6
Abbreviation: AML, acute myeloid leukaemia.
Molecular characterisation of AML by targeted capture
N Conte et al
1821
& 2013 Macmillan Publishers Limited Leukemia (2013) 1820 – 1825
somatic-sniper/current/)16 on the bam files using the default parameters
and VarScan (v2.3, http://varscan.sourceforge.net/)17 on the pileup files
using both the default mode and a high-sensitivity mode setting a
minimum variant frequency of 0.01, a normal purity of 0.95 and a tumour
purity of 0.20. In order to be able to compare the results with the calls
made by our software, the raw data generated by the other callers were
afterwards filtered according to the frequency and ratios criteria specified
in the above paragraph.
The predicted protein consequences of variations were derived using
Variant Effect Predictor from Ensembl, http://www.ensembl.org/info/docs/
variation/vep/index.html.
Validation of mutations and copy number changes identified by
next-generation sequencing
All dominant clone mutations were confirmed using PCR and capillary
sequencing. PCR was performed with Platinum Taq Polymearse (Invitrogen
Corporation, Carlsbad, CA, USA) for 35 cycles at 56 1C annealing and 72 1C
extension for 30 s. To amplify across the breakpoint of the MLL-partial tandem
duplication, we used LongAmp 2x Taq mastermix (New England Biolabs,
Ipswich, MA, USA) for 35 cycles at 57 1C annealing and 65 1C extension for
3min. PCR for detection of FLT3-internal tandem duplication was performed
as described previously.18 Mutant reads were visualised using IGV (Integrative
Genomics Viewer; http://www.broadinstitute.org/igv/bam). To verify the two
PTEN deletions, we used six known single-nucleotide polymorphisms within
introns of the PTEN gene. We amplified these by PCR, followed by second-
round PCR with barcoded Illumina adapter primers and sequencing on a
MiSeq sequencer. We used these results to look for evidence of copy number
change for one of the two alleles compared with a reference normal (P6 vs
ctrl) or a paired remission sample (P2 vs P2CR). All primer sequences are given
in Supplementary Table S1.
RESULTS
Analysis of our sequencing data showed a mean coverage depth
of 5136 per nucleotide position within the target region
(Figure 2). The 10 and 100 coverage were 96.4% and 94.8%,
respectively, for the desired target region (that is, all exons of
34 genes) (Supplementary Table S2), with most of the remaining
3.6–5.2% representing repetitive regions for which baits could not be
designed. With regards to substitutions and indels among the seven
AMLs studied, our mutation caller, MIDAS, identified 20 exonic and
one intronic mutations in the main leukaemic clone (2–4 mutations
per AML, Table 2). The same 20 exonic mutations were identified by
the VarScan platform and all were successfully validated using
Sanger sequencing (Supplementary Figure S2), giving both MIDAS
and VarScan 100% specificity for this data set. SomaticSniper, which
was designed for the identification of substitutions but not indels,
performed slightly less well (Supplementary Table S3). Of the 20
exonic mutations, 11 were single-base non-synonymous substitu-
tions at known sites (9 missense and 2 nonsense) and 9 were small
indels (8 associated with premature termination and 1 with a single
amino-acid insertion).
Figure 2. Distribution of the depth of sequencing coverage of the
target genes. Representative data from sample P1 showing the
fraction of bases covered at incremental depth windows (blue bars
and left hand y axis) and the cumulative fraction of bases covered at
or above the specified coverage (orange line and right hand y axis).
This shows that B88% of bases were covered at by at least 1000x
sequencing reads.
Mutation
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Figure 1. Workflow diagram for data analysis and mutation calling. After initial parsing of sequencing data through a series of open source
software tools, mutation calling is performed by our in-house Perl script (MIDAS). Mutational consequences are then determined by Variant
Effect Predictor, Ensembl. For the purposes of comparing MIDAS with other callers, SomaticSniper and VarScan were used instead.
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In order to determine whether the read depth for our target
regions correlated with DNA copy number, we compared
standardised read numbers for two X-linked genes, HPRT and
KDM6A, between male and female cases, and contrasted this
with the same ratio for the remaining (autosomal) genes. This
demonstrated that female cases displayed approximately twice
the number of normalised reads of male cases for the two X-linked
genes (F:M ratios of 2.0 for KDM6A and 1.91 for HPRT), signifying
that read numbers approximately reflect copy number in the
starting DNA. In keeping with this, male and female cases gave
similar normalised read numbers (M:F ratios close to 1) for the
32 autosomal genes (Supplementary Figure S3). Samples that
deviated from this ratio were later found to harbour copy number
variation at the relevant gene locus in one or more samples (for
example, CYP2D6 and PTEN). Furthermore, the quantitative nature
of the data was evident at the level of individual exons and not
just whole genes (for example, Supplementary Figure S5),
demonstrating that the data were quantitative even at the level
of small independently captured loci.
Given the above, we went on to look for copy number
aberrations involving the target exons using the Tukey Box-plot
method. The only autosomal gene loci exhibiting a significantly
increased coefficient of variability at multiple exons were CYP2D6,
MLL and PTEN (Supplementary Figure S4). CYP2D6 is known to
exhibit copy number variation and per exon read numbers were in
keeping with one individual (P3) having a lower CYP2D6 copy
number than the others (Supplementary Figure S5b). In the case
of PTEN, two samples (P2 and P6) had lower read numbers
(Supplementary Figure S5c), suggesting that these two cases of
AML may harbour deletions involving PTEN. To confirm this using
our limited material, we looked at differential allelic read counts
for six intronic single-nucleotide polymorphisms within the PTEN
locus, using PCR amplification followed by sequencing on a MiSeq
sequencer. Our results confirm copy number change at the PTEN
locus for P2 by demonstrating a preferential reduction in read
counts from one allele of two independent informative single-
nucleotide polymorphisms when compared with the matched
remission sample (P2CR) (Supplementary Table S4). In the case of
P6, only one single-nucleotide polymorphisms was informative
and although this was suggestive of copy number loss, we
cannot be completely confident this is the case in the absence
of a matched normal sample. In the case of MLL, one sample
(P6) showed an increased number of normalised reads for exons
2–9 only, suggesting the presence of a partial tandem duplication
(Figures 3a and b and Supplementary Figure S5d). This was also
identified by analysis using the ExomeCopy package19
(Supplementary Figure S6). The presence of a partial tandem
duplication was confirmed using PCR primers to amplify the
region spanning the junction (Figure 2c).
We went on to analyse our data to identify single-nucleotide
substitutions uniquely present in putative leukaemic
subclones representing as few as 1% of cells. We identified
putative subclonal mutations representing 3–20% of reads in
four leukaemic samples: (i) a FLT3 internal tandem duplication
in sample P3, which was flagged as a series of indels and
substitutions and confirmed by PCR (we went on to test all seven
AML samples for FLT3-internal tandem duplication and only
sample P3 was positive—data not shown), (ii) NRAS-G12S and
PTPN11-Q506P mutations in sample P5. The latter two mutations
occurred in 4.4% and 4.1% of reads, respectively, in keeping with
possible co-occurrence in the same subclone, (iii) FLT3-N676K in
sample P4 and (iv) TP53-G374fs*8 in sample P4Rel (Supplementary
Table S5). Finally, we analysed the two paired diagnosis-remission
samples (P1 vs P1CR and P2 vs P2CR) to look for evidence of
residual mutant reads in each remission sample. Both remission
samples were in morphological complete remission, but sample
P1CR was taken after four courses and sample P2CR after one
course of chemotherapy. At a level of sensitivity of at least 0.1%,T
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we found no mutant reads in sample P1CR, while sample P2CR
gave residual mutant reads representing 1.5–2.4% of total reads
for all three mutations identified at diagnosis (Supplementary
Table S6).
DISCUSSION
Advances in sequencing technologies are revolutionising cancer
research with somatic mutations underlying most major cancers
being avidly identified and characterised in large numbers of
cases. Concurrently, clinical and functional studies are defining the
diagnostic/prognostic significance of mutations and determining
their molecular effects in order to device targeted therapeutic
strategies. AML is at the forefront of such progress, and as a result
a significant body of information has already been gathered about
this leukaemia that can be used to guide clinical practice.
To date, most diagnostic laboratories use allele-specific
technologies to identify mutations in genes such as NPM1 and
FLT3, which have validated prognostic and therapeutic signifi-
cance.7,20,21 Additionally, newer technologies have been shown to
reliably identify leukaemia-associated mutations in larger numbers
of amplicons using pyrosequencing.22 However, the increasing
number of clinically relevant genes found mutated in AML make
conventional amplicon-based approaches impractical, particularly
as many such genes can harbour mutations in multiple different
locations and exons.23,24 Additionally, the clear demonstration
that many AMLs are composed of multiple subclones that can be
differentially susceptible to existing therapies10 suggests that
accurate therapeutic stratification of patients would benefit from
the identification of such clones at first presentation.
We describe a method based on targeted DNA capture
with cRNA baits followed by deep sequencing that enables the
simultaneous identification of mutations in 24 AML genes,
including the 10 most frequently mutated in AML–NK, without
recourse to normal constitutional DNA from the same individual.
Somatic mutations in the dominant leukaemic clone were
identified in all cases studied using sequence alignment/confi-
guration with open source software followed by mutation calling
using our in-house mutation caller MIDAS (Figure 2). The same
mutations were identified by the mutation caller VarScan17 and all
mutations so identified were validated using capillary sequencing,
demonstrating 100% specificity for both callers for our data set.
By contrast, no novel polymorphisms or mutations were identified
in 10 control genes known to be mutated in solid tumours
or leukaemias other than AML.
The sequencing depth reached in this study also enabled us to
identify putative mutations present in subclones at the time of
diagnosis. It is already clear that, compared with the main clone,
such subclones may be differentially sensitive to chemotherapy
and can expand to become the dominant clone at the time
of disease relapse,10 making their identification at the time of
diagnosis important. Nevertheless, at this stage, such subclonal
mutations need to be validated using independent metho-
dologies as it remains possible that they represent sequencing
or other forms of error.
Additionally, after confirming that our data behaved in a
quantitative manner with respect to input DNA copy number in
9 of 10 DNAs studied, we went on to identify copy number
variants in leukaemic samples, including an instance of MLL-partial
tandem duplication and two instances of probable loss of
PTEN, one of which we were able to validate. In analysing these
data it became clear that the lack or copy number information
from neighbouring genomic regions made analysis more difficult,
and we recommend that future studies of this kind endeavour to
capture several features around regions of possible copy number
loss to enhance both the power and the reliability of analyses.
Finally, we were able to demonstrate evidence of minimal residual
disease in a bone marrow DNA sample in morphological complete
remission by mining reads from the specific mutations in the
remission sample. Quantification of minimal residual disease after
induction chemotherapy may have prognostic implications in a
heterogeneous disease such as AML–NK and could be employed
in interventional studies to determine its significance.
We describe a molecular diagnostic method that enables
extensive molecular characterisation of AML–NK at diagnosis
and can facilitate clinical management of patients as well as
clinical research into this disease. The approach is powerful,
reliable and can be introduced into routine clinical practice in
order to enhance our ability to identify patients at high risk of
relapse as well as those that would benefit from molecularly
directed therapies and can also be adapted for minimal residual
disease monitoring. The sequencing methodology is modular and
target regions can be increased to include any newly discovered
gene mutations without significant changes to laboratory
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Figure 3. Identification of MLL partial tandem duplication (PTD) using sequencing read depth. Normalised per exon sequencing read depths
for the first 14 exons of MLL show increased depth for exons 2–9 from sample P6 (a). This suggested the presence of an exon 2 to exon 9 PTD
with a breakpoint in intron 9 (b). PCR amplification across the putative breakpoint using an exon 9 forward (MLL_9F) and an exon 2 reverse
(MLL_2R) primer confirms the presence of the PTD in this AML sample (c).
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protocols and with only marginal increases in costs. Additionally,
we provide a clear analytical workflow employing MIDAS, a novel
mutation calling algorithm available on request, which correctly
identified 20/20 exonic mutations present in 420% of reads. The
blueprint presented here can be used to study other haemato-
logical or solid tumours, or groups of tumours with overlapping
mutational spectra.
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